BofA upgraded BioCryst (BCRX) to Buy from Neutral with a $10 price target. Lead asset Orladeyo is the "sole driver" to the firm's valuation, contributing $12 per share, offset by negative net present value for pipeline spending, the analyst tells investors.
BioCryst Pharmaceuticals: BofA upgraded BioCryst (BCRX) to Buy from Neutral with a $10 price target